Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Ping An Good Doctor and Wyeth Reached Strategic Cooperation

SHANGHAI, May 15, 2019 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited("Ping An Good Doctor", or the "Company"; stock code: 01833.HK) announced strategic cooperation with Wyeth Nutrition on15 May 2019. Both sides will utilize their strengths in their respective fields for an all...

2019-05-15 15:20 5873

FDA Approves BAVENCIO® (avelumab) plus Axitinib Combination for Patients with Advanced Renal Cell Carcinoma

DARMSTADT, Germany and NEW YORK, May 15, 2019 /PRNewswire/ -- Not intended for US, Canada and UK-based media * BAVENCIO is the first anti-PD-L1 in combination with axitinib approved by FDA for first-line treatment of patients with advanced renal cell carcinoma (RCC) * Phase III study show...

2019-05-15 08:25 3587

Pneuma Respiratory and Leads Biolabs, Inc. Announce Partnership

BOONE, North Carolina, May 15, 2019 /PRNewswire/ -- Pneuma Respiratory, Inc., developer of a proprietary breath-activated digital inhaler (BDI), and Leads Biolabs Inc. announce an agreement granting Pneuma an exclusive license to develop Leads Biolabs' panel of immuno-oncology monoclonal antibodi...

2019-05-15 07:53 2277

Sekisui Diagnostics Invests $1.9 million in Microbial Biopharma CDMO Business

LEXINGTON, Massachusetts, May 15, 2019 /PRNewswire/ -- Sekisui Diagnostics Enzyme business announces the completion of a newBioProcess Innovation Centre at the site in Maidstone, Kent by the end of 2019, following a$1.9 million investment. This investment is part of a long-term investment strateg...

2019-05-15 03:11 2227

Sekisui Diagnostics Invests $1.9 million in Microbial Biopharma CDMO Business

Peritech Pharma Granted Patents for China and Russia

HERZLIYA, Israel, May 14, 2019 /PRNewswire/ -- Peritech Pharma , a specialty anal-rectal pharmaceutical company, today announced it has been granted patents coveringChina and Russia for its drug delivery platform used for two of its over-the-counter products, PP-110 f...

2019-05-14 08:55 3180

Frost & Sullivan Publishes Annual Update on BioLineRx

TEL AVIV, Israel, May 13, 2019 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise investor awareness to TASE listed technology and life-science companies and the markets in which these companies operate, thus creating appropriate pricing and increasing the exposure o...

2019-05-13 23:46 1184

NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA

LUND, Sweden, May 10, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's ...

2019-05-10 15:05 5673

Ally Bridge Group Leads Pulmonx's $65 Million Financing, Further Strengthening Its Global Medtech Franchise

HONG KONG, May 10, 2019 /PRNewswire/ -- Ally Bridge Group ("ABG"), a leading global life science investment group, announced today that it led an over-subscribed$65 million financing of Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device technologies with its key p...

2019-05-10 10:05 3109

Kazia calls for greater awareness of the most lethal women's disease in Australia

SYDNEY, May 8, 2019 /PRNewswire/ -- This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of what is the most lethal women's disease in Australia. Every year, approximately 1,600 Australian women are...

2019-05-08 09:55 6349

Two Clinical Studies with IBI301, a Biosimilar Candidate to Rituximab, Met Primary Endpoints

SUZHOU, China, May 8, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801) and Eli Lilly and Company ("Lilly") jointly announced today that IBI301, a recombinant human-mouse chimeric anti-cell surface protein (anti-CD20) monoclonal antibody being co-developed as a potential bios...

2019-05-08 08:00 8065

Connect Biopharma Reports Positive Phase 1 Data and Announces Initiation of Phase 1b Study in Patients with Atopic Dermatitis for Novel IL-4Rα Antibody CBP-201

TAICANG, China, May 6, 2019 /PRNewswire/ -- Connect Biopharma today announced that it has successfully completed a phase 1 single ascending dose (SAD) study of its novel IL-4Rα antibody, CBP-201. The randomized, double-blind, placebo-controlled study, conducted inMelbourne, Australia, evaluated t...

2019-05-06 17:00 882

Scientific Advisory Board Announced for DELopen to Guide the Open Access DNA Encoded Library Interchange

SHANGHAI and BOSTON, May 6, 2019 /PRNewswire/ -- DELopen, a new platform dedicated to the hit generation of drug discovery of DNA Encoded Library (DEL) Technology, has announced the formation of its Scientific Advisory Board. The board, chaired by Dr. Richard Lerner, Institute Professor of Scripp...

2019-05-06 13:38 1429

Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. Announce Strategic Alliance to Discover, Develop and Commercialize Innovative Biologics

CAMBRIDGE, Mass., ROTTERDAM, Netherlands, and SHANGHAI, May 6, 2019 /PRNewswire/ -- Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. (CTTQ) today announced they are entering into a strategic alliance to discover, develop and commercialize next-generation biologics for multiple thera...

2019-05-06 10:49 1765

CStone and Numab announce exclusive regional licensing agreement for ND021, a multi-functional drug candidate and potential next-generation immunotherapy

SUZHOU, China and ZURICH, May 2, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone"; HKEX: 2616) and Numab Therapeutics AG ("Numab") today announce that they have entered into an exclusive regional licensing agreement for the development and commercialization of ND021, a potential best-in-clas...

2019-05-02 11:05 3607

1 ... 177 178 179 180181